Item 6. EXHIBITS


Exhibit Number				Exhibit

3.1			Amended and Restated Articles of Incorporation of the Company, as amended and restated effective June 27, 2022, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 28, 2022.

3.2			Bylaws of the Company, as amended effective October 4 , 202 3 , incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on October 5 , 202 3 .

4.7			Upon the request of the U.S. Securities and Exchange Commission, the Company will furnish copies of any other instruments defining the rights of holders of long-term debt of the Company or its subsidiaries.



10.9	(d)	*	F o rm of Emp loy ment Agre ement between the Company and Ma rk Kaye.

10.11		*	O ffer Letter, by and between t he Company and Mark Kaye, dated as of August 2, 2023, incorporated by reference to Exhibit 10.1 to the Company ’s Current Report on Form 8-K filed on August 8, 2023.

23			C onsent of Independent Registered Public Accounting Firm.

31.1			Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act Rules, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2			Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act Rules, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1			Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2			Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

99.1			Recast of certain financial information and related disclosures initially included in Part I, Item 1 “Business,”, Part II Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” Part II Item 8. “Financial Statements and Supplementary Data” and Part IV Item 15 (c) “Financial Statement Schedule” of our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed on February 15, 2023 .

101			The following material from this Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, formatted in Inline XBRL (Inline Extensible Business Reporting Language): (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Income; (iii) the Consolidated Statements of Comprehensive Income; (iv) the Consolidated Statements of Cash Flows; (v) the Consolidated Statements of Changes in Equity; (vi) Notes to Consolidated Financial Statements; and (vii) the information under Part II, Item 5, “Other Information.” The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

104			Cover Page Interactive Data File formatted in Inline XBRL and contained in Exhibit 101.


*			Indicates management contracts or compensatory plans or arrangements.

-59-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



	ELEVANCE HEALTH, INC. Registrant



October 18, 2023	By:	/S/ JOHN E. GALLINA
		John E. Gallina Executive Vice President and Chief Financial Officer (Duly Authorized Officer and Principal Financial Officer)


October 18, 2023	By:	/S/ RONALD W. PENCZEK
		Ronald W. Penczek Chief Accounting Officer and Controller (Principal Accounting Officer)

-60-

Previous: Item 5. OTHER INFORMATION